Coverage to Cash Flow: Commercialization for HealthTech
Updated: Sep 23
Every Product Milestone Needs a Commercial Counterpart
Healthcare companies often organize development as a sequence. Build the product, validate it, secure reimbursement, launch, and sell. That sequence looks orderly, but it creates a dangerous gap. By the time the product is ready, the company may discover that the evidence does not support the buyer’s decision, the workflow does not fit the customer, or the sales cycle is longer than the runway.
Commercialization works better as a parallel discipline. At every stage of product development, the company should make a matching decision about the customer, payment path, evidence, price, message, and operating model. Coverage becomes cash flow only when those pieces reinforce one another.
Product concept and market concept should develop together
The first question is not whether the technology can be built. It is whether a defined customer has a costly or urgent problem and can act on the solution.
Early market analysis should identify who uses the product, who influences adoption, who pays, and who benefits financially. Those may be different people. A patient may use a tool, a clinician may recommend it, a health plan may fund it, and an employer may select the benefit. Each stakeholder needs a reason to support the model.
This is also the right time to assess reimbursement and programmatic funding. If an existing code applies, the company should understand coverage, documentation, site-of-care, and payment. If claims-based reimbursement is unlikely, the product may need to fit a payer program, employer benefit, provider budget, or direct-to-consumer model.
The decision affects features. A payer-funded product may require eligibility files, claims integration, reporting, security controls, and member outreach. A provider tool may need workflow integration and a clear labor or revenue effect. A consumer product needs an immediate value proposition strong enough to support acquisition and retention.
Design the evidence for the future claim
Clinical studies often establish that an intervention can work. Commercial evidence must also support why a buyer should adopt, fund, and renew it.
Before selecting endpoints, the company should define the claim it expects to make. Will the product reduce avoidable utilization, improve a quality measure, shorten staff time, increase treatment completion, or create a more attractive benefit? The study population, comparison, duration, and data collection should reflect that intended value story.
This does not mean allowing marketing to dictate science. It means ensuring that valid research also answers a decision-relevant question. A statistically significant outcome that cannot be linked to workflow, economics, or a buyer priority may have limited commercial use.
Evidence planning should include the timing of results. A health plan may need proof within a renewal cycle, while the clinical outcome requires longer follow-up. Intermediate indicators like activation, adherence, completed visits, or closed gaps, can show progress if their relationship to the final outcome is credible.
Use market readiness to remove adoption friction
As the product approaches launch, the company should move from secondary research to direct validation. Interviews with payers, providers, employers, patients, and channel partners can reveal procurement expectations, data needs, security barriers, workflow constraints, and pricing resistance.
These conversations should begin before the offer is fixed. A fully baked product can be difficult to adapt when the buyer exposes a fundamental mismatch. Early discussions allow the company to test a pilot design, understand budget ownership, and learn the language used inside the customer organization.
Market readiness also includes implementation. Contracts, privacy terms, security certifications, integrations, training, support, member communications, clinical escalation, and reporting should be designed as part of the offering. A buyer evaluates the total burden, not only the product interface.
Sales timing must reflect the market. The webinar notes that payer cycles that once appeared to take six to nine months may now require 12 to 24 months. Hospital decisions can also take many months. A company that hires an expensive sales team just before launch may be funding a learning period longer than anticipated.
Founder-led selling should produce a repeatable system
Founders are often the best early sellers because they can explain the vision, adapt the offer, and make product decisions in real time. The purpose of founder-led sales, however, is not to keep the founder at the center forever. It is to discover a repeatable motion.
The rule of three is suggested. That is, secure several health-plan customers with different sizes, geographies, and pricing structures before assuming the pattern is understood. Three contracts do not prove universal product-market fit, but they can reveal which elements repeat and which depend on one relationship.
That learning should be documented. Ideal customer profile, entry point, buyer committee, sales stages, objections, evidence, pricing, implementation, renewal criteria, and expansion path should become a system another person can follow.
Hiring a sales leader before this pattern exists can shift discovery to an expensive employee who lacks the founder’s authority to change the product. Hiring after the pattern is visible allows the team to scale a process rather than invent one under a quota.
Adoption requires its own growth strategy
Closing the contract is the beginning of commercialization, not the end. Digital health value depends on enrollment, use, clinical follow-through, and sustained engagement. Provider technologies depend on workflow adoption and repeated behavior.
Post-launch growth should include audience education, customer enablement, key opinion leader development, competitor monitoring, outcomes publication, and continuous product improvement. A buyer that cannot activate members or clinicians will struggle to realize the promised value and is less likely to renew.
The webinar’s surgical-robotics example shows how peer education can expand adoption. Creating centers where clinicians could observe and learn the use of an attachment helped grow the treating-physician base from 12 to 55. The product remained the same; the adoption infrastructure changed.
Another example used a focused professional campaign to reach thousands of physicians, generate more than 100 qualified leads, and support material revenue growth. The broader point is that awareness should be engineered around trusted channels and a clearly defined audience.
Treat expansion as a new market decision
Once a product has traction, expansion can look like simple replication. New customer segments often require different evidence, economics, compliance, and product capabilities.
A company moving from personal-injury use into workers’ compensation and health plans, for example, enters distinct payment systems and buying committees. Security requirements such as SOC 2 or HITRUST may become gating items. Pricing may shift from case-based to population-based. The value story must be recalculated for each buyer.
Expansion should therefore repeat the commercialization process, in that it defines the problem, target market, payment path, price, message, and delivery model. Success in one segment provides assets and evidence, but it does not eliminate the need for validation.
Build the commercialization thread into the roadmap
A useful roadmap pairs each technical milestone with a commercial question:
Product concept: Who experiences the problem, and who can pay to solve it?
Prototype: Which workflow and budget does the solution enter?
Study design: What buyer claim will the evidence support?
Market-ready product: What integration, security, and implementation barriers remain?
Initial contracts: Which parts of the sales motion repeat?
Launch: How will members or clinicians adopt?
Expansion: What changes in the new segment’s economics and requirements?
This integrated approach protects runway and sharpens decisions. It prevents a company from reaching launch with a product that is clinically sound but commercially incomplete.
Cash flow is not the final step after coverage. It is the outcome of many aligned choices made throughout development. Companies that treat commercialization as a continuous design discipline arrive at market with evidence, economics, and execution built into the product itself.
About the Speakers
Megan Doberstein, MBA
Commercial Marketing Leader at Ignite MedTech
Megan is Principal of Ignite MedTech, a fractional CMO agency supporting MedTech and HealthTech startups. With more than a decade of healthcare marketing experience, she helps companies build launch processes, market reach, internal momentum, and a stronger foundation for revenue growth. Connect with Megan on LinkedIn.
Demi Radeva, MSc
Founder and Chief Strategist at Akros Advisory
Demi has more than a decade of experience across Medicaid, Medicare, and Commercial health plans, including leadership roles at UnitedHealthcare and Optum. She now advises HealthTech companies on reimbursement, payer strategy, market access, and commercialization. Connect with Demi on LinkedIn.
Comments